Cetera Investment Advisers Outlook Therapeutics, Inc. Transaction History

Cetera Investment Advisers

  • $41.3 Billion
  • Q1 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023
BUY
$0.2 - $1.78 $621 - $5,530
3,107 Added 23.98%
16,065 $3,000
Q2 2023

Aug 09, 2023
BUY
$1.02 - $1.89 $1,186 - $2,198
1,163 Added 9.86%
12,958 $22,000
Q1 2023

May 15, 2023
BUY
$1.0 - $1.35 $11,795 - $15,923
11,795 New
11,795 $12,000

Others Institutions Holding OTLK

# of Institutions
7
Shares Held
67.1K
Call Options Held
0
Put Options Held
0
View Full List

About Outlook Therapeutics, Inc.

OTLK Quotes by TradingView
  • Ticker OTLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 226,144,992
  • Market Cap $1.66B
  • Description
  • Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...
More about OTLK
Track This Portfolio

Track Cetera Investment Advisers Portfolio

Follow Cetera Investment Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cetera Investment Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Cetera Investment Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email